SCHEMBL12425796

SCHEMBL12425796

Cc1ccc2sc(Cc3cccc([C@@H]4O[C@H](COCc5ccccc5)[C@@H](OCc5ccccc5)[C@H](OCc5ccccc5)[C@H]4OCc4ccccc4)c3)cc2c1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 2/20 0.43
SSTR1 P30872 2/20 0.38
SSTR2 P30874 2/20 0.38
SSTR4 P31391 2/20 0.38
SSTR3 P32745 2/20 0.38
SSTR5 P35346 2/20 0.38
TACR2 P21452 3/20 0.38
HTR1A P08908 1/20 0.36
BCHE P06276 1/20 0.35
PTPN1 P18031 6/20 0.35
CDC25B P30305 6/20 0.35
PTPN2 P17706 2/20 0.35
PTPN6 P29350 2/20 0.35
PTPN11 Q06124 2/20 0.35
NT5E P21589 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5522850 0.90 SLC5A2 (0.53) SLC5A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL12601465 0.90 SLC5A2 (0.53) SLC5A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL22330637 0.90 SLC5A2 (0.53) SLC5A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL12425812 0.90 SLC5A2 (0.42) SLC5A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL12425802 0.89 SLC5A2 (0.45) SLC5A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL12425799 0.89 SLC5A2 (0.43) SLC5A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL12425817 0.89 SLC5A2 (0.41) SLC5A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL12425811 0.89 SLC5A2 (0.41) SLC5A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL12425821 0.87 SLC5A2 (0.40) SLC5A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL12509917 0.86 SLC5A2 (0.41) SLC5A2SSTR1SSTR2SSTR4SSTR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977466-B2 C-glycoside derivatives and salts thereof ASTELLAS PHARMA INC. (JP) 2011-07-12 US disclosed
US-7772407-B2 C-glycoside derivatives and salts thereof ASTELLAS PHARMA INC. (JP) 2010-08-10 US disclosed
US-20090069252-A1 C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF ASTELLAS PHARMA INC. (JP) 2009-03-12 US disclosed
US-20070161787-A1 C-glycoside derivatives and salts thereof ASTELLAS PHARMA INC. (JP) 2007-07-12 US disclosed
US-7202350-B2 C-glycoside derivatives and salts thereof ASTELLAS PHARMA INC. (JP) 2007-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161787-A1 C-glycoside derivatives and salts thereof SLC5A1, SLC5A2, SLC2A1 SLC5A2 2/4885SSTR1 650/4885SSTR2 781/4885
US-20090069252-A1 C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF SLC5A1, SLC5A2, SLC2A1 SLC5A2 2/4885SSTR1 650/4885SSTR2 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.